A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Rondo Therapeutics
Novartis
Carisma Therapeutics Inc
Pfizer
Novartis
Daiichi Sankyo
Novartis
Santa Maria Biotherapeutics
Imunon
Novartis
Celldex Therapeutics
Merck Sharp & Dohme LLC
Bristol-Myers Squibb